About Us
Muscular Dystrophy Association Awards Eight Grants Totaling More Than $2 Million for ALS Research
Critical Funding Provided by MDA Will Support ALS Researchers and Clinicians in the Areas of Gene Editing, Biomarker-Informed Treatment, Targeted Therapies and Disease Progression
NEW YORK, April 8, 2019 /PRNewswire/ -- Ahead of ALS Awareness Month in May, the Muscular Dystrophy Association (MDA) announced today the awarding of eight new MDA grants totaling more than $2 million toward research focused on amyotrophic lateral sclerosis (ALS). This pledge reinforces MDA's unwavering commitment to the progress of scientific and clinical ALS research and builds on the more than $165 million MDA has already invested in ALS. Later this month, the impact of critical research efforts, such as those funded by MDA, will come to life at the annual MDA Clinical and Scientific Conference, themed "Progress in Motion" (April 14-17, Orlando, FL), where MDA will convene over 1,100 neuromuscular disease (NMD) scientists, clinicians, regulators, and advocates to reveal and discuss the latest in ALS and other NMD research.
Answering crucial questions to speed therapy development
The newly funded projects will promote therapy development on multiple fronts. The awarded grants include studies to help provide a better understanding of what causes ALS and pinpoint new drug targets, to develop improved therapeutic strategies, and to ensure that the right tools such as biomarkers are in place to pave the way for successful clinical trials. MDA is also committed to maintaining a robust pipeline of promising early-stage scientists who will make the important discoveries of tomorrow.
Grant awardees for this grant cycle include:
Thomas Gaj, PhD
University of Illinois, Urbana-Champaign
Research grant, $300,000
Dr. Gaj will evaluate whether gene editing can be a potential treatment for ALS caused by mutations in the superoxide dismutase 1 gene (SOD1), estimated to cause about 2% of all ALS cases. Scientists believe that mutations in the SOD1 gene cause the superoxide dismutase 1 protein (SOD1) to adopt abnormal toxic functions, leading to the loss of motor neurons that causes ALS. Dr. Gaj will employ a new kind of gene-editing technique that can alter a gene sequence without breaking the DNA, unlike traditional gene-editing tools.
Tania Gendron, PhD
Mayo Clinic, Jacksonville, Fla.
Research grant, $285,000
As many as half of all ALS patients will develop impairments in cognition during their disease course. Dr. Gendron will identify protein biomarkers in blood and spinal fluid that may be useful to predict which ALS patients may develop cognitive impairments. These biomarkers could be helpful to improve patient care as well as inform how clinical trials should be designed.
Jonathan Glass, MD
Emory University, Atlanta, Ga.
Research infrastructure grant, $151,592
The NEALS Consortium is an international organization of 125 research sites that collaborate to support and conduct clinical research in ALS and other motor neuron diseases. This grant will help support the NEALS Consortium's biorepository, which contains tissues and fluids that are widely used by the community — including MDA-funded researchers — to advance ALS research. The grant will also support the annual NEALS Consortium meeting, where NEALS clinicians share advances and receive training.
Junjie Guo, PhD
Yale University
Research grant, $297,678
A mutation in the C9ORF72 gene in which one segment of the gene is repeated too many times — also known as a repeat expansion — is the most common cause of the familial form of ALS (referred to as C9-ALS). Dr. Guo will study how RNA foci (clumps, or aggregates), which can become toxic to cells, are formed, what factors regulate their formation, and how these foci affect RNA metabolism in a C9-ALS motor neuron model. This work could improve understanding of the role that RNA foci play in ALS and other repeat expansion-associated neuromuscular diseases.
Csaba Konrad, PhD
Weill Cornell Medical College, New York, N.Y.
Development grant, $210,000
Developing drugs to treat ALS has proven difficult because there are many causes of the disease, resulting in a highly diverse patient population and a dearth of biomarkers. Biomarkers can be used for predicting disease progression and response to therapy, early detection, and patient stratification in clinical trials — making biomarker discovery for ALS a high priority. Dr. Konrad will use his large bank of skin cells derived from non-familial ALS patients to determine if the cells can be clustered into groups based on changes in size and shape. He hopes to use these models to discover improved biomarkers for ALS.
John Landers, PhD
University of Massachusetts Medical School
Research grant, $300,000
Scientists have identified more than 40 genes that cause familial ALS; some of them have also been found in non-familial ALS patients. Still, there is no definitive genetic root for 90 percent of ALS cases. Dr. Landers will apply his funding to identifying novel therapeutic targets for both familial and non-familial ALS. He will use RNAi (RNA interference) screens, in which RNA molecules bind to and inactivate genes, to discover novel drug targets for ALS.
Ze'ev Melamed, PhD
Ludwig Institute for Cancer Research, University of California, San Diego
Development grant, $210,000
Dr. Melamed's grant will help to determine how suppression of stathmin-2 protein, recently shown to be decreased in the motor neurons of non-familial ALS patients, drives motor neuron degeneration and whether reversal of stathmin-2 defects could have therapeutic potential for ALS. He will also work with Ionis Pharmaceuticals to develop an antisense oligonucleotide (a type of therapy that uses genetic material to target a specific gene or genetic sequence) designed to have a therapeutic effect in motor neurons of patients with ALS.
Marka Van Blitterswijk, MD, PhD
Mark Ebbert, PhD
Mayo Clinic, Jacksonville, Fla.
Research grant, $300,000
Discovery of the C9ORF72 gene repeat expansion has provided some knowledge of ALS disease mechanism, but it's still unknown how or whether interruptions in the repeated genetic material affect disease variability, development, and progression. Dr. Van Blitterswijk will use a novel technology to analyze the C9ORF72 gene mutation in clinical samples from ALS patients to determine whether the size of the mutation can be used to predict factors such as survival time and cognitive changes. It could eventually pave the way for future therapies and diagnostics based on the variability found in the repeat expansion. This work is a collaboration with the lab of Mark Ebbert, PhD.
About ALS
MDA ALS Impact Sheet
MDA ALS Fact Sheet
ALS is a disease of the parts of the central nervous system that control voluntary muscle movement. In ALS patients, motor neurons (nerve cells that control muscle cells) gradually lose function, causing muscles to become weak and eventually nonfunctional. The majority of cases of ALS are sporadic, meaning there is no known family history of the disease. However, up to 10 percent of cases are familial, meaning the disease is inherited or passed down within a family. Life expectancy is typically three to five years after diagnosis, and there is no cure.
ALS is a devastating disease that doesn't discriminate. Anytime anyone is diagnosed with ALS, MDA is here, supporting patients, families, and caregivers. Whether providing world-class care or investing in innovative research and technology, MDA has led the way, with decades or progress against ALS.
About MDA
MDA is committed to transforming the lives of people affected by muscular dystrophy, ALS and related neuromuscular diseases. We do this through innovations in science and innovations in care. As the largest source of funding for neuromuscular disease research outside of the federal government, MDA has committed more than $1 billion since our inception to accelerate the discovery of therapies and cures. Research we have supported is directly linked to life-changing therapies across multiple neuromuscular diseases. MDA's MOVR is a transformative platform, combining MDA's Care Center Network with a state-of-the-art information management system to improve health outcomes for neuromuscular disease patients and accelerate drug development. MDA supports the largest network of multidisciplinary clinics providing best-in-class care at more than 150 of the nation's top medical institutions. Our Resource Center serves the community with one-on-one specialized support, and we offer educational conferences, events and materials for families and health care providers. Each year, thousands of children and young adults learn vital life skills and gain independence at MDA Summer Camp and through recreational programs, at no cost to families. For more information, visit mda.org.
SOURCE Muscular Dystrophy Association
